Nacuity Pharmaceuticals develops targeted therapies to address oxidative tissue damage, which is associated with eye diseases and serious chronic conditions. The company has clinical programs for conditions such as retinitis pigmentosa, cataract, and cystinosis.

Nacuity Pharmaceuticals

SERI Lugano is involved in research and innovation in vision, focusing on advanced ophthalmic treatments and therapies for various eye conditions.

SERI Lugano

Dry Eye Centre specializes in the analysis and treatment of mild to severe dry eyes, self-described as the first clinic in the UK dedicated solely to this.

Dry Eye Centre

Nacuity Pharmaceuticals, Inc. | 459 followers on LinkedIn. Leader in innovative treatments for oxidative stress | Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of many blinding eye diseases and a broad spectrum of serious chronic conditions. Powered by key backing and technical support from the world’s leading private funders of retinal disease research, Foundation Fighting Blindness and RD Fund, Nacuity is pursuing near-term proof-of-concept data in several of its highly differentiated clinical programs, including retinitis pigmentosa, cataract, and cystinosis, with the potential to be first-of-a-kind therapies and gateways to wider applications.

President at Opus Genetics

Ben Yerxa

Vice President Integrated Drug Development & Certara Global Health Lead

Kevin Hershberger

Managing Director, RD Fund

Rusty Kelley

Owner - Talisman Healthcare

Daniel Feller

Nacuity Pharmaceuticals, Inc.

Nacuity has become aware that purported “recruiters” are fraudulently posing as representatives of Nacuity. These “recruiters” are reaching out on social media with fake offers of employment and asking potential “recruits” for personal and banking information. These “recruiters” do not represent Nacuity. They are completely unaffiliated with Nacuity. It is a scam. Nacuity is not actively recruiting at this time. No representative of Nacuity is soliciting personal or banking information. Image Description: Nacuity logo on white background with the text: "Beware: Fraudulent Recruiter Contact"

Our SVP and CSO, G. Michael Wall, Ph.D. , attended the American Association of Pharmaceutical Scientists Annual Meeting ( #PharmSci360 ) this week in Salt Lake City, UT. Dr. Wall had the opportunity to learn about the latest updates during the scientific sessions and liaise with global contract research and manufacturing organizations necessary for our drug development programs. Image description for photo #1: Dr. Michael Wall at AAPS opening session Image description for photo #2: Dr. Michael Wall in front of windows overlooking AAPS exhibit floor

G. Michael Wall, Ph.D. , our SVP and CSO, attended CPHI Milan, October 8-10, 2024. Chemical and Pharmaceuticals Ingredients (CPhI) Worldwide is the world’s largest pharma event, a 3-day exhibition bringing together more than 47,000 professionals and 2,600 exhibitors from more than 150 countries. Dr. Wall successfully identified sources for materials and services necessary for Nacuity’s drug development programs. Image Description: Dr. Michael Wall in Fiera Milano exhibition center #CPHI2024 #CPHIMilan

We look forward to joining our peers in #ophthalmology to learn more about the latest innovations at #AAO2024 in Chicago this week! We’re also excited for our onsite board of directors and scientific advisory board meetings. Check out this year’s program: https://lnkd.in/dCK33m7

Today is #WorldSightDay and this year is focused on children’s eye health. Eye diseases, like RP associated with Usher syndrome, are often diagnosed during childhood. Vision is critical to a child’s development. Join the International Agency for the Prevention of Blindness (IAPB) to take the pledge to make children’s eye health and awareness a priority! https://brnw.ch/21wMEaU

For #BlindnessAwarenessMonth , the Foundation Fighting Blindness ’ #ShareYourVision campaign invites individuals experiencing #VisionLoss to share their stories and unique experiences of life after diagnosis. We’re proud to join FFB to share patient stories and help raise awareness of blinding #EyeDiseases . Follow the #ShareYourVision hashtag to learn more!

This Sunday is #WorldRetinaDay and World #RetinitisPigmentosa Day (RP). The retina makes vision possible and retinal diseases like #RP lead to #VisionLoss in millions of people worldwide. Our commitment to patients affected by blinding #EyeDiseases drives our work to develop our #OxidativeStress therapies for the treatment of RP and more. Image Description: Photo of eye and Nacuity Pharmaceuticals logo on green and blue background with the text "September 29 World Retina Day & World Retinitis Pigmentosa Day"

Finding treatments and cures for rare diseases like Usher syndrome is often limited by insufficient research and funding, making spreading awareness for #UshDay a critical part of our mission to improve the lives of people experiencing #visionloss . Join us and the #UsherSyndrome community to help shine a light on this inherited disease. Image Description: Photo of child putting glasses on doll and Nacuity Pharmaceuticals logo on green and blue background with the text "September 21 Usher Syndrome Awareness Day 400,000 people worldwide are affected by #USH ."

Although #UsherSyndrome (USH) is considered a #raredisease , it’s the leading cause of combined deafness and #blindness worldwide. We’re advancing our clinical trial evaluating of our NPI-001 tablets to treat #retinitispigmentosa associated with #USH to improve the lives of individuals with USH. Learn more and follow our progress: https://lnkd.in/etgtbbHV Image Description: Spotlight on Usher Syndrome logo at the top left with text below that says, "An estimated 25,000 people in the U.S. have Usher syndrome. Worldwide, it is the leading cause of combined deafness and blindness." To the right is a blue DNA double helix.

We’re a proud sponsor of the Usher Syndrome Coalition 's USH Connections Conference. #USH2024 is an important opportunity to connect #UsherSyndrome patients and families with researchers working to advance #USH treatments and professionals serving the #DeafBlind community. Learn more: https://lnkd.in/edWnwR8s

Metric
Company Name	Nacuity Pharmaceuticals	SERI Lugano	Dry Eye Centre
Symbol
MSH ID	COM:NACUITY	CH:SERI-LUGANO	UK:CO:DRYEYECENTRE
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Medical & Healthcare	Medical Services
Country	US	CH	GB
Stage	Series B
Employee Count
Website	nacuity.com	seri-lugano.ch	dryeyecentre.co.uk
LinkedIn	nacuity-pharmaceuticals-inc	seri-lugano
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	226
Web Traffic Growth	-0.34
Valuation
Raised Capital	16.50M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

NACU

COM:NACUITY

Nacuity Pharmaceuticals

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue